Recently, targeting SP clinically has been shown to be an effective anti-pruritic treatment in various conditions, including skin cancer-associated itch (70) as well as in patients with various skin disorders such as atopic dermatitis and prurigo nodularis (71), although negligible evidence is currently available in psoriasis-associated discomfort. The gene discussed is TFF2; the disease is prurigo nodularis.